14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
8 citations
,
January 1987 in “Gynecological Endocrinology” Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
May 2026 in “European Cells and Materials” The new delivery system improves Alzheimer's symptoms by releasing Huperzine A slowly and effectively.
April 2010 in “Nature Reviews Urology”
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.
February 2012 in “Community oncology” The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
November 2020 in “Journal of The American Academy of Dermatology” Ankle braces reduce motion, while external focus improves hip and knee movements.
11 citations
,
January 2018 in “DOAJ (DOAJ: Directory of Open Access Journals)” A 4-year-old boy with a rare type of rickets and hair loss improved in bone health but not hair growth after vitamin D and calcium treatment.
6 citations
,
August 2020 in “Dermatology and Therapy” People with Alopecia Areata often have lower vitamin D levels, and vitamin D supplements might help treat it.
July 2025 in “JAAD Case Reports” April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
50 citations
,
June 1999 in “Annals of Oncology” Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
Baricitinib works better than methotrexate for severe alopecia areata.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
52 citations
,
April 2002 in “Brain Research” Lower allopregnanolone levels increase stress-related dopamine release in the brain.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
July 2026 in “Journal of the American Academy of Dermatology” February 2026 in “Macromolecular Bioscience” Keratin-based hydrogels with calcium are effective for delivering anti-fibrotic drugs.
May 2013 in “UTUPub (University of Turku)” Including androgens in hormone therapy may lower breast cancer risk.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
51 citations
,
April 1999 in “The Journal of Steroid Biochemistry and Molecular Biology” Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.
December 2024 in “Ukrainian Journal of Dermatology Venerology Cosmetology” "Alpenta" effectively reduces hair loss and improves hair growth in women with telogen effluvium.
2 citations
,
March 2025 in “ESMO Open” Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.